康希諾生物(06185.HK)預計2023年度淨虧損12.7億到14.97億元
格隆匯1月30日丨康希諾生物(06185.HK)公吿,經公司初步測算,預計截至2023年12月31日止年度實現歸屬於母公司所有者的淨虧損為人民幣1,268.5百萬元到人民幣1,496.9百萬元。
預計截至2023年12月31日止年度實現歸屬於母公司所有者的扣除非經常性損益的淨虧損為人民幣1,377.0百萬元到人民幣1,624.9百萬元。
報吿期內,隨着集團流腦疫苗產品商業化進程的推進,產品持續導入市場,流腦疫苗產品相關銷售收入較去年同期大幅增長。集團的MCV4曼海欣為我國首個腦膜炎球菌四價結合疫苗產品,定位於嬰幼兒非免疫規劃高端疫苗市場,為我國嬰幼兒流腦疾病的預防提供更優解決方案。
集團歸屬於母公司所有者的淨虧損較比去年同期增加的主要原因為:由於新冠疫苗市場需求變化,集團新冠疫苗相關收入較同期大幅下降;基於新冠疫苗產品實際接種情況及對未來接種情況的預期,集團對已經發生的及未來可能發生的新冠疫苗產品退回金額進行核算及合理估計,並於報吿期內衝減新冠疫苗產品收入;營業成本方面,因新冠疫苗產量較低,相關產線產能利用率不足,集團將該部分宂餘產能對應的固定成本計入營業成本;考慮新冠疫苗相關存貨和長期資產的未來使用計劃,集團對存在減值跡象的存貨、應收退貨成本、預付賬款和長期資產進行了減值測試,並根據測試結果計提減值損失;同時,報吿期內,集團為持續推廣流腦疫苗產品增加行銷活動推廣,銷售費用較同期增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.